Elahere — Net revenues

Products & Services · Net revenues

AbbVie Elahere — Net revenues increased by 7.1% to $182.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 23.0%, from $148.00M to $182.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market adoption and growing demand for the therapy, while a decrease may signal increased competition or loss of market share.

Detailed definition

This metric represents the total gross sales of the Elahere product line minus returns, allowances, and rebates. It serv...

Peer comparison

Comparable to revenue metrics for specific oncology assets or specialty pharmaceutical products at peer biopharmaceutical companies.

Metric ID: abbv_segment_elahere_net_revenues

Historical Data

16 periods
 Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$64.00M$128.00M$139.00M$148.00M$179.00M$159.00M$170.00M$182.00M
QoQ Change+100.0%+8.6%+6.5%+20.9%-11.2%+6.9%+7.1%
YoY Change+179.7%+24.2%+22.3%+23.0%
Range$0.00$182.00M
Avg YoY Growth+62.3%
Median YoY Growth+23.6%
Current Streak2 quarters growth

Frequently Asked Questions

What is AbbVie's elahere — net revenues?
AbbVie (ABBV) reported elahere — net revenues of $182.00M in Q4 2025.
How has AbbVie's elahere — net revenues changed year-over-year?
AbbVie's elahere — net revenues increased by 23.0% year-over-year, from $148.00M to $182.00M.
What does elahere — net revenues mean?
The total net sales generated by the Elahere pharmaceutical product.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.